In addition, our study identified eight patients without HER2 expression in tumor tissues but expressing HER2 in CTCs, showing a worse prognosis when they were treated with cytotoxic agents without combined HER2-targeted therapy. The gene discussed is ERBB2; the disease is neoplasm.